4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.70 | -0.07 | 0.21 | -0.11 |
| FCF Yield | -9.51% | -20.94% | -26.87% | -15.58% |
| EV / EBITDA | -8.30 | -2.63 | -1.36 | -2.88 |
| Quality | ||||
| ROIC | -15.59% | -13.37% | -10.84% | -10.45% |
| Gross Margin | -52,386.67% | -319,573.33% | 100.00% | -178,300.00% |
| Cash Conversion Ratio | 0.82 | 0.79 | 1.00 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -82.39% | -75.64% | -78.16% | -77.22% |
| Free Cash Flow Growth | -6.82% | 10.22% | -3.37% | -50.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 0.93 | 2.11 | 2.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -13.08 | -16.33 | 0.00 | -221.27 |